{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:04:41Z","timestamp":1778216681881,"version":"3.51.4"},"reference-count":114,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:00:00Z","timestamp":1679702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)\/MCTES","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)\/MCTES","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)\/MCTES","award":["2021.06472.BD"],"award-info":[{"award-number":["2021.06472.BD"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy (i4HB)","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy (i4HB)","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]},{"name":"Associate Laboratory Institute for Health and Bioeconomy (i4HB)","award":["2021.06472.BD"],"award-info":[{"award-number":["2021.06472.BD"]}]},{"name":"FCT","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}]},{"name":"FCT","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}]},{"name":"FCT","award":["2021.06472.BD"],"award-info":[{"award-number":["2021.06472.BD"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Nanoparticles include particles ranging in size from nanometers to micrometers, whose physicochemical characteristics are optimized to make them appropriate delivery vehicles for drugs or immunogens important in the fight and\/or prevention of infectious diseases. There has been a rise in the use of nanoparticles in preventive vaccine formulations as immunostimulatory adjuvants, and as vehicles for immunogen delivery to target immune cells. Toxoplasma is important worldwide, and may cause human toxoplasmosis. In immunocompetent hosts, infection is usually asymptomatic, but in immunocompromised patients it can cause serious neurological and ocular consequences, such as encephalitis and retinochoroiditis. Primary infection during pregnancy may cause abortion or congenital toxoplasmosis. Currently, there is no effective human vaccine against this disease. Evidence has emerged from several experimental studies testing nanovaccines showing them to be promising tools in the prevention of experimental toxoplasmosis. For the present study, a literature review was carried out on articles published over the last 10 years through the PubMed database, pertaining to in vivo experimental models of T. gondii infection where nanovaccines were tested and protection and immune responses evaluated. This review aims to highlight the way forward in the search for an effective vaccine for toxoplasmosis.<\/jats:p>","DOI":"10.3390\/vaccines11040733","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T04:05:40Z","timestamp":1679889940000},"page":"733","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Nanoparticles as a Delivery System of Antigens for the Development of an Effective Vaccine against Toxoplasma gondii"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-7187","authenticated-orcid":false,"given":"Carina","family":"Brito","sequence":"first","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"given":"Camila","family":"Louren\u00e7o","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9421-0444","authenticated-orcid":false,"given":"Joana","family":"Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"LAQV, REQUIMTE, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-2835","authenticated-orcid":false,"given":"Salette","family":"Reis","sequence":"additional","affiliation":[{"name":"LAQV, REQUIMTE, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-4095","authenticated-orcid":false,"given":"Margarida","family":"Borges","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13071-021-04769-4","article-title":"Outbreaks of clinical toxoplasmosis in humans: Five decades of personal experience, perspectives and lessons learned","volume":"14","author":"Dubey","year":"2021","journal-title":"Parasites Vectors"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1038\/s41598-018-24361-8","article-title":"Seroprevalence of Toxoplasma gondii in pregnant women and livestock in the mainland of China: A systematic review and hierarchical meta-analysis","volume":"8","author":"Deng","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/encyclopedia2010012","article-title":"The Apicomplexan Parasite Toxoplasma gondii","volume":"2","author":"Delgado","year":"2022","journal-title":"Encyclopedia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1093\/cid\/ciaa428","article-title":"Toward Improving Interventions Against Toxoplasmosis by Identifying Routes of Transmission Using Sporozoite-specific Serological Tools","volume":"71","author":"Milne","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.puhe.2007.08.009","article-title":"Congenital toxoplasmosis: Priorities for further health promotion action","volume":"122","author":"Elsheikha","year":"2008","journal-title":"Public Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2352-3018(17)30005-X","article-title":"Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15092","DOI":"10.1038\/s41598-022-16420-y","article-title":"Association between Toxoplasma gondii infection and psychiatric disorders: A cross-sectional study in China","volume":"12","author":"Liu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Silva, M.d., Teixeira, C., Gomes, P., and Borges, M. (2021). Promising Drug Targets and Compounds with Anti-Toxoplasma gondii Activity. Microorganisms, 9.","DOI":"10.3390\/microorganisms9091960"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e12690","DOI":"10.1111\/pim.12690","article-title":"Toxoplasma gondii infection reduces serum progesterone levels and adverse effects at the maternal-foetal interface","volume":"42","author":"Brito","year":"2020","journal-title":"Parasite Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"951584","DOI":"10.3389\/fvets.2022.951584","article-title":"Advances in vaccine development and the immune response against toxoplasmosis in sheep and goats","volume":"9","author":"Hasan","year":"2022","journal-title":"Front. Veter-Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41587-021-01085-1","article-title":"Nanotechnology offers alternative ways to fight COVID-19 pandemic with antivirals","volume":"39","author":"Peplow","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1038\/s41598-019-42645-5","article-title":"3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15","volume":"9","author":"Rasmussen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"001","DOI":"10.14411\/fp.2019.001","article-title":"Nanoparticles show potential to retard bradyzoites in vitro formation of Toxoplasma gondii","volume":"66","author":"Adeyemi","year":"2019","journal-title":"Folia Parasitol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.smim.2017.09.007","article-title":"Modulating the immune system through nanotechnology","volume":"34","author":"Dacoba","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpara.2008.08.002","article-title":"The immunobiology of the innate response to Toxoplasma gondii","volume":"39","author":"Miller","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2180-14-76","article-title":"Overproduction of Toxoplasma gondii cyclophilin-18 regulates host cell migration and enhances parasite dissemination in a CCR5-independent manner","volume":"14","author":"Ibrahim","year":"2014","journal-title":"BMC Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12606","DOI":"10.1111\/pim.12606","article-title":"How does toxoplasmosis affect the maternal-foetal immune interface and pregnancy?","volume":"41","author":"Borges","year":"2019","journal-title":"Parasite Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-444-53490-3.00008-X","article-title":"Toxoplasmosis","volume":"114","author":"Halonen","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12964-019-0471-y","article-title":"The regulatory roles of neutrophils in adaptive immunity","volume":"17","author":"Li","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1074-7613(03)00230-9","article-title":"TRAF6 Is a Critical Factor for Dendritic Cell Maturation and Development","volume":"19","author":"Kobayashi","year":"2003","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mihret, A., Mamo, G., Tafesse, M., Hailu, A., and Parida, S.K. (2011). Dendritic Cells Activate and Mature after Infection with Mycobacterium tuberculosis. BMC Res. Notes, 4.","DOI":"10.1186\/1756-0500-4-247"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/IAI.73.2.703-711.2005","article-title":"Class I Major Histocompatibility Complex Presentation of Antigens That Escape from the Parasitophorous Vacuole of Toxoplasma gondii","volume":"73","author":"Gubbels","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.pt.2011.03.009","article-title":"Innate responses to Toxoplasma gondii in mice and humans","volume":"27","author":"Pifer","year":"2011","journal-title":"Trends Parasitol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/1040-840291046731","article-title":"Macrophage-Mediated Innate Host Defense Against Protozoan Parasites","volume":"28","author":"Stafford","year":"2002","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"03946320221078436","DOI":"10.1177\/03946320221078436","article-title":"Immune response against toxoplasmosis\u2014Some recent updates RH: Toxoplasma gondii immune response","volume":"36","author":"Sana","year":"2022","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gigley, J.P. (2016). The Diverse Role of NK Cells in Immunity to Toxoplasma gondii Infection. PLOS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005396"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-065X.2010.00992.x","article-title":"Immunology of Toxoplasma gondii","volume":"240","author":"Munoz","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6152489","DOI":"10.1155\/2019\/6152489","article-title":"Toxoplasma gondii Modulates the Host Cell Responses: An Overview of Apoptosis Pathways","volume":"2019","author":"Mammari","year":"2019","journal-title":"BioMed Res. Int."},{"key":"ref_30","first-page":"573825","article-title":"IL-17-expressing CD4\u207a and CD8\u207a T lymphocytes in human toxoplasmosis","volume":"2014","author":"Silva","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1128\/IAI.73.1.617-621.2005","article-title":"Interleukin-17\/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection","volume":"73","author":"Kelly","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.12688\/f1000research.7010.1","article-title":"Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells","volume":"4","author":"Ma","year":"2015","journal-title":"F1000Research"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43042-019-0006-5","article-title":"Toxoplasmosis and abortion: Pro- and anti-inflammatory cytokines gene expression of the host immune cells","volume":"20","author":"Attia","year":"2019","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/mi.2010.8","article-title":"IL-10 production by CD4+ effector T cells: A mechanism for self-regulation","volume":"3","author":"Jankovic","year":"2010","journal-title":"Mucosal Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.icb.7100038","article-title":"Cytokine regulation of immunopathology in toxoplasmosis","volume":"85","author":"Gaddi","year":"2007","journal-title":"Immunol. Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.diagmicrobio.2015.09.009","article-title":"Serological diagnosis of Toxoplasma gondii infection: Recommendations from the French National Reference Center for Toxoplasmosis","volume":"84","author":"Villard","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_37","first-page":"71","article-title":"Immune response to Toxoplasma gondii","volume":"40","author":"Filisetti","year":"2004","journal-title":"Ann. Ist. Super. Sanit\u00e0"},{"key":"ref_38","first-page":"2032057","article-title":"The Effects of Secretory IgA in the Mucosal Immune System","volume":"2020","author":"Li","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/JCM.39.6.2267-2271.2001","article-title":"Strategy for Diagnosis of Congenital Toxoplasmosis: Evaluation of Methods Comparing Mothers and Newborns and Standard Methods for Postnatal Detection of Immunoglobulin G, M, and A Antibodies","volume":"39","author":"Pinon","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Pietrzak, B., Tomela, K., Olejnik-Schmidt, A., Mackiewicz, A., and Schmidt, M. (2020). Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239254"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/JCM.37.11.3487-3490.1999","article-title":"Detection of specific immunoglobulin E during maternal, fetal, and congenital toxoplasmosis","volume":"37","author":"Villena","year":"1999","journal-title":"J. Clin. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zierhut, M., Pavesio, C., Ohno, S., Orefice, F., and Rao, N.A. (2016). Intraocular Inflammation, Springer.","DOI":"10.1007\/978-3-540-75387-2"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40824-019-0166-x","article-title":"Therapeutic efficacy of nanoparticles and routes of administration","volume":"23","author":"Chenthamara","year":"2019","journal-title":"Biomater. Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Dobrovolskaia, M.A., and McNeil, S.E. (2013). Handbook of Immunological Properties of Engineered Nanomaterials, World Scientific.","DOI":"10.1142\/8390"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vaccine.2013.11.069","article-title":"Nanoparticle vaccines","volume":"32","author":"Zhao","year":"2014","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1101\/gad.226837.113","article-title":"Nanotechnology: Emerging tools for biology and medicine","volume":"27","author":"Wong","year":"2013","journal-title":"Genes Dev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.021","article-title":"Nanoparticles\u2014A historical perspective","volume":"331","author":"Kreuter","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1021\/ja203340u","article-title":"Large-Scale Synthesis of Uniform and Extremely Small-Sized Iron Oxide Nanoparticles for High-Resolution T1 Magnetic Resonance Imaging Contrast Agents","volume":"133","author":"Kim","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Crommelin, D.J.A., Sindelar, R.D., and Meibohm, B. (2019). Pharmaceutical Biotechnology: Fundamentals and Applications, Springer International Publishing.","DOI":"10.1007\/978-3-030-00710-2"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"204ra130","DOI":"10.1126\/scitranslmed.3006516","article-title":"Generation of Effector Memory T Cell\u2013Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination","volume":"5","author":"Li","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for Cancer Therapy: Current Progress and Challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3762\/bjnano.9.98","article-title":"Review on nanoparticles and nanostructured materials: History, sources, toxicity and regulations","volume":"9","author":"Jeevanandam","year":"2018","journal-title":"Beilstein J. Nanotechnol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle Vaccines Against Infectious Diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"195101","DOI":"10.1088\/0957-4484\/21\/19\/195101","article-title":"Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide","volume":"21","author":"Chen","year":"2010","journal-title":"Nanotechnology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ejps.2011.10.012","article-title":"Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant","volume":"44","author":"Wang","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1039\/C2NR32145A","article-title":"Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells","volume":"5","author":"Yu","year":"2013","journal-title":"Nanoscale"},{"key":"ref_58","first-page":"29","article-title":"Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles","volume":"433","author":"Grego","year":"2021","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Nogueira","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"705886","DOI":"10.3389\/fbioe.2021.705886","article-title":"Liposomes: Structure, Biomedical Applications, and Stability Parameters with Emphasis on Cholesterol","volume":"9","author":"Nakhaei","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13543776.2020.1720649","article-title":"Solid lipid nanoparticles: A review on recent perspectives and patents","volume":"30","author":"Paliwal","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"580118","DOI":"10.3389\/fchem.2021.580118","article-title":"Lipid Nanoparticles as Carriers for Bioactive Delivery","volume":"9","author":"Dhiman","year":"2021","journal-title":"Front. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chis, A.A., Dobrea, C., Morgovan, C., Arseniu, A.M., Rus, L.L., Butuca, A., Juncan, A.M., Totan, M., Vonica-Tincu, A.L., and Cormos, G. (2020). Applications and Limitations of Dendrimers in Biomedicine. Molecules, 25.","DOI":"10.3390\/molecules25173982"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1556-276X-9-247","article-title":"Dendrimers: Synthesis, applications, and properties","volume":"9","author":"Abbasi","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nantod.2019.04.005","article-title":"Designing inorganic nanomaterials for vaccines and immunotherapies","volume":"27","author":"Hess","year":"2019","journal-title":"Nano Today"},{"key":"ref_69","first-page":"8","article-title":"Solid lipid nanoparticles- A review","volume":"5","author":"Yadav","year":"2013","journal-title":"International Journal of Applied Pharmaceutics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Petkar, K.C., Patil, S.M., Chavhan, S.S., Kaneko, K., Sawant, K.K., Kunda, N.K., and Saleem, I.Y. (2021). An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040455"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jconrel.2017.03.033","article-title":"Synthetic nanovaccines for immunotherapy","volume":"263","author":"Luo","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3488","article-title":"Applications of nanotechnology for immunology","volume":"13","author":"Smith","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2010.03.027","article-title":"Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response","volume":"145","author":"Christensen","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"12530","DOI":"10.1002\/jcp.28120","article-title":"Nanovaccine: A novel approach in immunization","volume":"234","author":"Hayat","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_76","first-page":"CD012805","article-title":"Aluminium adjuvants used in vaccines versus placebo or no intervention","volume":"2017","author":"Djurisic","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.coi.2010.04.004","article-title":"New adjuvants for human vaccines","volume":"22","author":"Mbow","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.vaccine.2015.10.132","article-title":"A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Vaccine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"10799","DOI":"10.1021\/nn4040553","article-title":"Cell Membranes Open \u201cDoors\u201d for Cationic Nanoparticles\/Biomolecules: Insights into Uptake Kinetics","volume":"7","author":"Lin","year":"2013","journal-title":"ACS Nano"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Juan, A., Cimas, F.J., Bravo, I., Pandiella, A., Oca\u00f1a, A., and Alonso-Moreno, C. (2020). An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090802"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3347\/kjp.2014.52.6.581","article-title":"Recent Advances in Toxoplasma gondii Immunotherapeutics","volume":"52","author":"Lim","year":"2014","journal-title":"Korean J. Parasitol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Chu, K.-B., and Quan, F.-S. (2021). Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9050413"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1051\/parasite\/2017013","article-title":"Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes","volume":"24","author":"Wang","year":"2017","journal-title":"Parasite"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14712598.2018.1413086","article-title":"Moving towards improved vaccines for Toxoplasma gondii","volume":"18","author":"Li","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.imlet.2017.03.006","article-title":"Enhancing immune responses to a DNA vaccine encoding Toxoplasma gondii GRA14 by calcium phosphate nanoparticles as an adjuvant","volume":"185","author":"Ahmadpour","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"787635","DOI":"10.3389\/fcimb.2021.787635","article-title":"Enhancing Immune Responses to a DNA Vaccine Encoding Toxoplasma gondii GRA7 Using Calcium Phosphate Nanoparticles as an Adjuvant","volume":"11","author":"Sun","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fmicb.2017.00605","article-title":"Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) Self-amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP)","volume":"8","author":"Luo","year":"2017","journal-title":"Front Microbiol"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Hasan, T., Kawanishi, R., Akita, H., and Nishikawa, Y. (2021). Toxoplasma gondii GRA15 DNA Vaccine with a Liposomal Nanocarrier Composed of an SS-Cleavable and pH-Activated Lipid-like Material Induces Protective Immunity against Toxoplasmosis in Mice. Vaccines, 10.","DOI":"10.3390\/vaccines10010021"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00436-016-5325-6","article-title":"Immunological evaluation of a DNA cocktail vaccine with co-delivery of calcium phosphate nanoparticles (CaPNs) against the Toxoplasma gondii RH strain in BALB\/c mice","volume":"116","author":"Rahimi","year":"2016","journal-title":"Parasitol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.biomaterials.2015.01.056","article-title":"Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection","volume":"50","author":"Carpentier","year":"2015","journal-title":"Biomaterials"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Yu, Z., Zhou, T., Luo, Y., Dong, L., Li, C., Liu, J., Luo, J., Yan, R., Xu, L., and Song, X. (2020). Modulation Effects of Toxoplasma gondii Histone H2A1 on Murine Macrophages and Encapsulation with Polymer as a Vaccine Candidate. Vaccines, 8.","DOI":"10.3390\/vaccines8040731"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1016\/j.vaccine.2018.08.068","article-title":"Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection","volume":"36","author":"Roozbehani","year":"2018","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/fmb-2016-0146","article-title":"Synthetic parasites: A successful mucosal nanoparticle vaccine against Toxoplasma congenital infection in mice","volume":"12","author":"Ducournau","year":"2017","journal-title":"Futur. Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3389\/fimmu.2020.02183","article-title":"Effective Nanoparticle-Based Nasal Vaccine Against Latent and Congenital Toxoplasmosis in Sheep","volume":"11","author":"Ducournau","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"104764","DOI":"10.1016\/j.micpath.2021.104764","article-title":"Protective efficacy by a novel multi-epitope vaccine, including MIC3, ROP8, and SAG1, against acute Toxoplasma gondii infection in BALB\/c mice","volume":"153","author":"Dodangeh","year":"2021","journal-title":"Microb. Pathog."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00436-016-5298-5","article-title":"Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii","volume":"116","author":"Nabi","year":"2016","journal-title":"Parasitol. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/21691401.2018.1478421","article-title":"Induction of Th1 type-oriented humoral response through intranasal immunization of mice with SAG1-Toxoplasma gondii polymeric nanospheres","volume":"46","author":"Naeem","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"105312","DOI":"10.1016\/j.micpath.2021.105312","article-title":"Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: An efficient vaccine against chronic toxoplasmosis","volume":"162","author":"Allahyari","year":"2022","journal-title":"Microb. Pathog."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ijbiomac.2022.03.146","article-title":"Novel naltrexone hydrochloride nanovaccine based on chitosan nanoparticles promotes induction of Th1 and Th17 immune responses resulting in protection against Toxoplasma gondii tachyzoites in a mouse model","volume":"208","author":"Khorshidvand","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"106215","DOI":"10.1016\/j.actatropica.2021.106215","article-title":"Effect of alginate nanoparticles on the immunogenicity of excretory-secretory antigens against acute toxoplasmosis in murine model","volume":"225","author":"Gaafar","year":"2022","journal-title":"Acta Trop."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s00436-021-07232-6","article-title":"The immune response against Toxoplasma gondii in BALB\/c mice induced by mannose-modified nanoliposome of excreted\/secreted antigens","volume":"120","author":"Abdollahi","year":"2021","journal-title":"Parasitol. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cimid.2018.09.012","article-title":"Quantification of Toxoplasma gondii in the tissues of BALB\/c mice after immunization with nanoliposomal excretory-secretory antigens using Real-Time PCR","volume":"59","author":"Azadi","year":"2018","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"ref_105","first-page":"77","article-title":"Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites","volume":"433","author":"Chu","year":"2021","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Lee, D.H., Lee, S.H., Kim, A.R., and Quan, F.S. (2016). Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161231"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Kang, H.-J., Lee, S.H., Kim, M.J., Chu, K.B., Lee, D.H., Chopra, M., Choi, H.J., Park, H., Jin, H., and Quan, F.-S. (2019). Influenza Virus-Like Particles Presenting both Toxoplasma gondii ROP4 and ROP13 Enhance Protection against T. gondii Infection. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11070342"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"103601","DOI":"10.1016\/j.micpath.2019.103601","article-title":"Protective efficacy induced by DNA prime and recombinant protein boost vaccination with Toxoplasma gondii GRA14 in mice","volume":"134","author":"Pagheh","year":"2019","journal-title":"Microb. Pathog."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1080\/21691401.2018.1469024","article-title":"Molecular docking of immunogenic peptide of Toxoplasma gondii and encapsulation with polymer as vaccine candidate","volume":"46","author":"Kokcu","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"726615","DOI":"10.3389\/fimmu.2021.726615","article-title":"With Chitosan and PLGA as the Delivery Vehicle, Toxoplasma gondii Oxidoreductase-Based DNA Vaccines Decrease Parasite Burdens in Mice","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"16984","DOI":"10.1038\/s41598-020-73210-0","article-title":"Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice","volume":"10","author":"Zhou","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e1703207","DOI":"10.1002\/smll.201703207","article-title":"Intranasal Nanovaccine Confers Homo- and Hetero-Subtypic Influenza Protection","volume":"14","author":"Qi","year":"2018","journal-title":"Small"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2007.11.027","article-title":"Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B","volume":"354","author":"Khatri","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/1348-0421.12027","article-title":"Enhanced protection against pulmonary mycobacterial challenge by chitosan-formulated polyepitope gene vaccine is associated with increased pulmonary secretory IgA and gamma-interferon+T cell responses","volume":"57","author":"Ai","year":"2013","journal-title":"Microbiol. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/4\/733\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:03:08Z","timestamp":1760122988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/4\/733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,25]]},"references-count":114,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["vaccines11040733"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11040733","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,25]]}}}